Jiangsu Bioperfectus Technologies Co., Ltd. (SHA:688399)
63.70
+2.91 (4.79%)
Aug 12, 2025, 2:45 PM CST
SHA:688399 Revenue
Jiangsu Bioperfectus Technologies had revenue of 91.61M CNY in the quarter ending March 31, 2025, with 0.54% growth. This brings the company's revenue in the last twelve months to 350.10M, down -12.53% year-over-year. In the year 2024, Jiangsu Bioperfectus Technologies had annual revenue of 349.61M, down -13.29%.
Revenue (ttm)
350.10M
Revenue Growth
-12.53%
P/S Ratio
15.26
Revenue / Employee
591.38K
Employees
592
Market Cap
5.34B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 349.61M | -53.57M | -13.29% |
Dec 31, 2023 | 403.18M | -5.13B | -92.72% |
Dec 31, 2022 | 5.53B | 2.70B | 94.95% |
Dec 31, 2021 | 2.84B | 1.10B | 63.19% |
Dec 31, 2020 | 1.74B | 1.45B | 502.39% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jiangsu Hengrui Medicine | 29.19B |
Shenzhen Mindray Bio-Medical Electronics | 35.59B |
WuXi AppTec | 41.48B |
Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
Aier Eye Hospital Group | 21.81B |
Sichuan Biokin Pharmaceutical | 5.82B |
Shanghai United Imaging Healthcare | 10.43B |
Yunnan Baiyao Group Co.,Ltd | 40.10B |